Spots Global Cancer Trial Database for Combination of Chemotherapy and Gefitinib as First-line Treatment

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Combination of Chemotherapy and Gefitinib as First-line Treatment

Official Title: Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial

Study ID: NCT02148380

Conditions

Non-Small-Cell Lung Cancer

Interventions

pemetrexed plus carboplatin

gefitinib

Study Description

Brief Summary: The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged PFS and OS of patients with NSCLC. However, outcome of the combination therapy are similar to those reported in several trials of single-agent EGFR TKIs. So which is the optimal first-line treatment for patients who harbored a sensitive EGFR mutation? The investigators need a head-to-head study to reply.

Detailed Description:

Keywords

Lung adenocarcinoma,EGFR mutation, chemotherapy, gefitinib

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Shanghai Chest Hospital, Shanghai, , China

Contact Details

Name: Baohui Han, Dr

Affiliation: Vice President of Shanghai Chest Hospital,Sponsor of study

Role: STUDY_CHAIR

Name: Bo Jin, Dr

Affiliation: Study Leader,Doctor of Shanghai Chest Hospital

Role: STUDY_DIRECTOR

Name: Yanjie Niu, Master